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BACKGROUND: Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) is associated with poor survival.
Platinum-based chemotherapy is often a first-line treatment. Pemetrexed has shown single-agent activity in SCCHN and in combina-
tion with cisplatin for other tumors. This trial examined the efficacy of pemetrexed-cisplatin for SCCHN. METHODS: In a double-blind
phase 3 trial, patients with recurrent or metastatic SCCHN and no prior systemic therapy for metastatic disease were randomized to
pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2; n ¼ 398) or placebo plus cisplatin (75 mg/m2; n ¼ 397) to assess overall survival
(OS) and secondary endpoints. RESULTS: Median OS was 7.3 months in the pemetrexed-cisplatin arm and 6.3 months in the placebo-
cisplatin arm (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.75-1.02; P ¼ .082). Median progression-free survival (PFS,
months) was similar in both treatment arms (pemetrexed-cisplatin, 3.6; placebo-cisplatin, 2.8; HR, 0.88; 95% CI, 0.76-1.03; P ¼ .166).
Among patients with performance status 0 or 1, pemetrexed-cisplatin (n ¼ 347) led to longer OS and PFS than placebo-cisplatin (n ¼
343; 8.4 vs 6.7 months; HR, 0.83; P ¼ .026; 4.0 vs 3.0 months; HR, 0.84; P ¼ .044, respectively). Among patients with oropharyngeal
cancers, pemetrexed-cisplatin (n ¼ 86) resulted in longer OS and PFS than placebo-cisplatin (n ¼ 106; 9.9 vs 6.1 months; HR, 0.59;
P ¼ .002; 4.0 vs 3.4 months; HR, 0.73; P ¼ .047, respectively). Pemetrexed-cisplatin toxicity was consistent with studies in other
tumors. CONCLUSIONS: Pemetrexed-cisplatin compared with placebo-cisplatin did not significantly improve survival for the intent-
to-treat population. However, in a prespecified subgroup analysis, pemetrexed-cisplatin showed OS and PFS advantage for patients
with performance status 0 or 1 or oropharyngeal cancers. Cancer 2012;118:4694-705. VC 2012 American Cancer Society.
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INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common type of cancer worldwide, with an
estimated 650,000 new cases and 350,000 deaths reported every year.1,2 Inoperable recurrent and metastatic SCCHNs
are generally incurable, thus treatment focuses on prolonging overall survival (OS) or progression-free survival (PFS), pal-
liating existing symptoms, and preventing new cancer-related symptoms.3,4 Multiple chemotherapeutic agents have been
shown to induce tumor responses; among these, cisplatin chemotherapy is frequently used for inoperable recurrent or met-
astatic SCCHN, either as a single agent or in combination with other chemotherapeutics.4,5 The historical median
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survival with cisplatin-based combination chemotherapy
ranges from 6 to 8 months, with a corresponding 1-year
survival rate of 20% to 40%.6,7
Pemetrexed, an inhibitor of thymidylate synthase
and other folate-dependent enzymes,8-10 has been investi-
gated in a phase 2 study of patients with SCCHN as a sin-
gle agent.11 In this study, 9 of the 34 evaluable patients
(26.5%) achieved a partial response (median time to treat-
ment failure, 3.9 months; median OS, 7.3 months).
These results, together with data from pilot studies inves-
tigating pemetrexed with cisplatin for SCCHN (data on
file) and data from trials in other solid tumors,12,13 sug-
gest that pemetrexed may have activity in patients with
recurrent or metastatic SCCHN. To explore this hypothe-
sis, a phase 3 trial was undertaken to compare the OS of
patients treated with pemetrexed plus cisplatin with that
of patients treated with single-agent cisplatin. Cisplatin
was chosen as the control arm because at the time of trial
initiation (2006), it was considered a standard well-toler-
ated treatment, and had been used as the comparator arm
in the 2005 phase 3 trial examining the combination of
cisplatin and the biological agent cetuximab.6 In addition,
single-agent cisplatin was chosen so as not to unnecessarily
increase the toxicity of the comparator arm, because at the
time, no platinum-based chemotherapy doublet had
improved survival time compared with single-agent ther-




Patient eligibility criteria included histological or cytolog-
ical diagnosis of recurrent SCCHN or newly diagnosed
distant metastatic SCCHN,6 months since completion
of chemotherapy or biological anticancer therapy, and no
prior systemic therapy for metastatic disease. Other inclu-
sion criteria were 18 years of age; life expectancy 3
months; Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 0, 1, or 217; measurable or
nonmeasurable disease status as defined by Response Eval-
uation Criteria in Solid Tumors (RECIST)18; and
adequate bone marrow reserve and organ function.
Protocol amendments approved after study initia-
tion included changing the requirement that prior surgery
and radiation be completed 6 months before study
enrollment to4 weeks before enrollment; this was more
in keeping with standard clinical practice. Another proto-
col change lowered the minimum required creatinine
clearance value19 from 60 to 45 mL/min based on clinical
evidence of the tolerability of the pemetrexed-cisplatin
regimen used in this study. In addition, a protocol change
provided for the collection of tumor tissue samples as for-
malin-fixed, paraffin-embedded tissue to study genes
involved in SCCHN biology and drug activity by micro-
array gene expression analysis. No results are available to
be reported because poor microarray performance yielded
no results.
Exclusion criteria included nasopharyngeal, para-
nasal sinus, lip, or salivary gland cancer; clinically signifi-
cant third-space fluid that could not be drained; and
central nervous system metastases. Patients were also
excluded if they were unable to interrupt therapy with as-
pirin or other nonsteroidal anti-inflammatory drugs, or if
they were unable or unwilling to take folic acid, vitamin
B12, or corticosteroids.
The study was conducted according to the Declara-
tion of Helsinki and Good Clinical Practice guidelines
and was approved by each participating institutional/
ethics review board. All patients provided written
informed consent before treatment.
Study Design and Treatment Plan
This was a global, double-blind, randomized, placebo
controlled phase 3 study. On day 1 every 21 days, patients
received pemetrexed 500 mg/m2 (10-minute infusion)
plus cisplatin 75 mg/m2 or placebo (100 mL saline) plus
cisplatin 75 mg/m2. The cisplatin dose was chosen to yield
a dose intensity of 25 mg/m2/wk, a dose intensity sup-
ported by previous randomized trials5,6,14 and shown to
be within the 20 to 40 mg/m2/wk range found to yield
equivalent efficacy in a randomized study comparing a
high and standard doses of cisplatin in the treatment of
advanced nonsmall cell lung cancer.20 Randomization
(1:1) by the technique of Pocock and Simon21 was used to
minimize imbalances among prognostic factors: baseline
ECOG PS (0 or 1 vs 2), prior treatment for SCCHN, dis-
tant metastases, prior platinum-based therapy, and
country.
Chemotherapy was administered for 6 cycles;
patients could be discontinued from the study before the
completion of the 6 cycles for disease progression, unac-
ceptable toxicity, or patient/physician decision. Addi-
tional cycles were permitted for patients receiving benefit
from study treatment. All patients were followed until
death or study closure. Patients on both arms received
prophylactic dexamethasone, oral folic acid, and vitamin
B12 injection as per the pemetrexed label. Because peme-
trexed, cisplatin, placebo, and vitamin B12 were adminis-
tered at the investigational sites by authorized study
personnel, patient compliance was ensured.
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The following were allowed per protocol: dose
adjustments (as per the pemetrexed label), cycle delays
42 days (to allow resolution of toxicities), and concomi-
tant supportive therapies (granulocyte colony-stimulating
factors or erythropoietin) according to the American Soci-
ety of Clinical Oncology guidelines.22
Baseline and Treatment Assessments
The primary efficacy measure was OS. Secondary end-
points included PFS, tumor response rate, safety, time to
worsening, and change from baseline in dimensions of
health-related quality of life (HRQL) using the Func-
tional Assessment of Cancer Therapy - Head and Neck
scale (FACT-H&N).23,24
Baseline tumormeasurements were performed within
4 weeks before first treatment dose. Computed tomogra-
phy ormagnetic resonance imaging was preferred, but chest
x-ray was acceptable for clearly defined lesions. Any palpa-
ble tumors weremeasured within 2 weeks of first treatment.
The baseline assessment method was repeated every other
cycle, and every 6 weeks after treatment discontinuation
until disease progression. Patients who had baseline imag-
ing and at least 1 scan after starting chemotherapy were
considered assessable for tumor response using RECIST
1.0.18 OS and PFS analyses incorporated all randomized
patients on an intention-to-treat (ITT) basis.
Patients were assessed for toxicity before each cycle
according to the Common Terminology Criteria for
Adverse Events, version 3.0.25 All patients who received at
least 1 dose of pemetrexed or cisplatin were considered
assessable for safety.
The FACT-H&N scale (version 4) was adminis-
tered at baseline and on day 1 of all cycles to assess and
compare changes in HRQL between treatment arms. This
reliable and valid instrument24 consists of a 39-item scale
organized into 5 subscales: physical, social/family, func-
tional, and emotional well-being, and additional con-
cerns-head and neck, with higher scores representing
better quality of life. The FACT-H&N scores were calcu-
lated based on scoring criteria proposed by the devel-
oper.23 Results of the FACT-H&N are reported as
follows: the scores for the 5 individual subscales; a FACT-
General total score (sum of all subscales excluding the
H&N subscale); a Trial Outcome Index-H&N (the sum
of the scores of the physical well-being, functional well-
being, and H&N cancer subscales); and Total FACT-
H&N score (the sum of the scores of all 5 subscales). Pro-
spectively defined minimally important differences were
used to calculate time to worsening and to interpret
change from baseline results.26
Statistical Analyses
The study was designed to enroll approximately 790
patients, with 1:1 randomization between the 2 arms. The
median OS with single-agent cisplatin was estimated to be
8 months6; the study was powered to detect a 25%
improvement in OS by showing a median OS of 10
months with pemetrexed-cisplatin. Assuming the true sur-
vival hazard ratio (HR) of pemetrexed-cisplatin to cispla-
tin alone was 0.80, the study had 80% power to achieve
significance at a 2-sided level of .05. An interim analysis
based on PFS was planned after approximately 300
patients had died or experienced disease progression to
assess safety and futility. An independent statistical analy-
sis group performed the analysis for the Data Monitoring
Committee. As reported herein, the final analysis compar-
ing OS between the arms was to be performed after 632
deaths had occurred (20% censoring rate). To compare
the time-to-event endpoints (including the primary end-
point, OS), a stratified log-rank test at a 2-sided a ¼ .05
was used, with the following prognostic factors as stratifi-
cation variables: PS (0 or 1 vs 2), previously treated for
SCCHN (no vs yes), distant metastasis (no vs yes), and
prior platinum-based therapy (no vs yes). The survival dis-
tributions were estimated using the Kaplan-Meier
method.27 The Kaplan-Meier estimations included
Kaplan-Meier curve, quartiles, and interval estimation
using 95% confidence intervals (CIs). Supportive analyses
were done to obtain treatment effect after adjusting for
the prognostic variables using the Cox regression model.28
Prespecified subgroup analyses for OS and PFS were
conducted on important subgroups of patients: ECOG
PS (0 or 1 vs 2), previously treated SCCHN (no vs yes),
prior platinum-based therapy (no vs yes), distant metasta-
sis (no vs yes), age (<50 vs 50 years), sex (male vs
female), race (Caucasian vs non-Caucasian), primary site
of disease (oral cavity, oropharynx, hypopharynx, larynx,
and other), and prior surgery or radiotherapy within 6
months of randomization (no vs yes). An unstratified log-
rank test was used to assess the treatment difference within
subgroups, and the Cox regression model was used to test
the treatment-by-subgroup interaction. Tumor responses
were compared between treatments using unadjusted nor-
mal approximation for differences in rates. The changes
from baseline in the FACT-H&N subscale scores were an-
alyzed using mixed-model repeated-measures analysis
with treatment, baseline score, visit, and treatment-by-
visit interaction as fixed effects, and with patient nested in
treatment as a random effect in the model; missing data
were assumed to be missing at random. The incidences of
toxicities, hospitalizations, and concomitant medication
use were analyzed using the Fisher exact test.
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RESULTS
Patients
Between December 2006 andMarch 2010, 114 investiga-
tors at 110 study sites in 20 countries (in Asia, Europe,
and North America) screened 952 patients. Among these,
795 were randomized (pemetrexed-cisplatin, n ¼ 398;
placebo-cisplatin, n ¼ 397; Fig. 1). The baseline patient
and disease characteristics were well balanced between the
treatment arms, and generally reflected the overall popula-
tion of patients with SCCHN (Table 1). The distribution
of disease sites reflects the global nature of the trial.
Within the PS subgroups (0 or 1 and 2), the treatment
arms were also balanced. The planned interim analysis
was performed in November 2008 after 301 events and
resulted in the decision to continue the study as planned.
Post-trial analysis showed the number of patients with
prior surgery or radiotherapy within 6 months of random-
ization was balanced between treatment arms (peme-
trexed-cisplatin, 20.2%; placebo-cisplatin, 19.8%).
Treatment
Seven hundred seventy-seven patients (97.7%) received
study treatment consisting of at least 1 dose of pemetrexed
or cisplatin (pemetrexed-cisplatin: n ¼ 392; placebo-cispla-
tin: n ¼ 385). A median of 4 cycles was administered on
the pemetrexed-cisplatin arm and 3 cycles on the placebo-
cisplatin arm. More pemetrexed-cisplatin patients com-
pleted 6 cycles than did placebo-cisplatin patients (126 vs
103, respectively), whereas more patients discontinued
from the placebo-cisplatin arm because of lack of efficacy or
progressive disease (217 vs 180, respectively; Fig. 1). The
dose intensity was similar for both arms; for pemetrexed-
cisplatin, it was 94% for pemetrexed and 91% for cisplatin;
for placebo-cisplatin, it was 96.0% each. Within the PS 0
or 1 subgroup, similar treatment trends were observed.
Dose adjustments (delays or reductions) were less
frequent in patients treated with placebo-cisplatin com-
pared with pemetrexed-cisplatin patients. On the peme-
trexed-cisplatin arm, there were 33 pemetrexed and 74
Figure 1. A CONSORT (Consolidated Standards of Reporting Trials) flow diagram shows patient disposition. Percentages do not
add up to 100 because of rounding. Cis, cisplatin; ITT, intention to treat; Pem, pemetrexed.
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cisplatin dose reductions; on the placebo-cisplatin arm,
there were 7 placebo and 55 cisplatin dose reductions.
The most common reasons for pemetrexed dose reduc-
tions were febrile neutropenia and neutropenia; for cispla-
tin (on both treatment arms), it was decreased creatinine
clearance.
Efficacy and HRQL
OS for ITT patients on the pemetrexed-cisplatin arm was
not superior to that for patients on the placebo-cisplatin
arm (Fig. 2A), with both arms having20% censoring and
similar use of postdiscontinuation systemic therapy (Table
2). The median OS times were 7.3 and 6.3 months for the
pemetrexed-cisplatin and placebo-cisplatin arms, respec-
tively (HR, 0.87; 95% CI, 0.75-1.02; P ¼ .082). The 1-
and 2-year survival probability rates were as follows: peme-
trexed-cisplatin arm, 30.0% and 9.0%; placebo-cisplatin
arm, 25.0% and 10.0%. The treatment effect on OS after
adjusting for baseline prognostic factors was similar to that
observed in the unadjusted analysis (HR, 0.89; 95% CI,
0.76-1.03; P¼ .125).
Table 1. Baseline Demographic and Disease Characteristics for ITT Population and PS Subgroups
Characteristic ITT
Population
















Median age, y 57.7 57.9 57.5 57.4 60.4 61.6
Range, y 32-79 21-84 32-79 21-82 33-75 39-84
Sex, No. (%)
Male 342 (85.9) 344 (86.6) 301 (86.7) 298 (86.9) 41 (80.4) 45 (84.9)
Female 56 (14.1) 53 (13.4) 46 (13.3) 45 (13.1) 10 (19.6) 8 (15.1)
Ethnicity, No. (%)
Caucasian 243 (61.1) 233 (58.7) 206 (59.4) 195 (56.9) 37 (72.5) 37 (69.8)
Western Asian (Indian subcontinent) 72 (18.1) 70 (17.6) 69 (19.9) 67 (19.5) 3 (5.9) 3 (5.7)
Eastern Asian 55 (13.8) 65 (16.4) 45 (13.0) 55 (16.0) 10 (19.6) 10 (18.9)
African 17 (4.3) 12 (3.0) 16 (4.6) 11 (3.2) 1 (2.0) 1 (1.9)
Hispanic 11 (2.8) 16 (4.0) 11 (3.2) 14 (4.1) 0 2 (3.8)
ECOG PS, No. (%)
0 or 1 347 (87.2) 343 (86.4) 347 (100) 343 (100) 0 0
2 51 (12.8) 53 (13.4) 0 0 51 (100) 53 (100)
Previously treated for SCCHN, No. (%)
Received ‡1 previous therapy 363 (91.2) 358 (90.2) 317 (91.4) 310 (90.4) 46 (90.2) 47 (88.7)
Chemotherapy 206 (51.8) 181 (45.6) 179 (51.6) 157 (45.8) 27 (52.9) 23 (43.4)
Radiotherapy 342 (85.9) 322 (81.1) 298 (85.9) 278 (81.0) 44 (86.3) 43 (81.1)
Chemoradiotherapy 162 (40.7) 139 (35.0) 140 (40.3) 122 (35.6) 22 (43.1) 17 (32.1)
Surgery 236 (59.3) 252 (63.5) 200 (57.6) 216 (63.0) 36 (70.6) 36 (67.9)
Prior surgery or radiotherapy, No. (%)
£6 months before randomization 81 (20.4) 89 (22.4) 70 (20.2) 68 (19.8) 11 (21.6) 21 (39.6)
>6 months before randomization 281 (70.6) 265 (66.8) 246 (70.9) 239 (69.7) 35 (68.6) 26 (49.1)
Never had radiotherapy or surgery 36 (9.0) 43 (10.8) 31 (8.9) 36 (10.5) 5 (9.8) 6 (11.3)
Prior platinum-based therapy, No. (%)
Yes 185 (46.5) 169 (42.6) 159 (45.8) 145 (42.3) 26 (51.0) 23 (43.4)
No 213 (53.5) 228 (57.4) 188 (54.2) 198 (57.7) 25 (49.0) 30 (56.6)
Distant metastasis, No. (%)
Yes 233 (58.5) 242 (61.0) 199 (57.3) 207 (60.3) 34 (66.7) 35 (66.0)
No 165 (41.5) 155 (39.0) 148 (42.7) 136 (39.7) 17 (33.3) 18 (34.0)
Primary site of disease, No. (%)
Oral cavity 138 (34.7) 123 (31.0) 119 (34.3) 111 (32.4) 19 (37.3) 12 (22.6)
Oropharynx 86 (21.6) 106 (26.7) 79 (22.8) 90 (26.2) 7 (13.7) 16 (30.2)
Hypopharynx 63 (15.8) 59 (14.9) 56 (16.1) 48 (14.0) 7 (13.7) 10 (18.9)
Larynx 103 (25.9) 102 (25.7) 85 (24.5) 89 (25.9) 18 (35.3) 13 (24.5)
Other 8 (2.0) 7 (1.8) 8 (2.3) 5 (1.5) 0 2 (3.8)
Abbreviations: Cis, cisplatin; ECOG, Eastern Cooperative Oncology Group; ITT, intention to treat; Pem, pemetrexed; PS, performance status; SCCHN, squa-
mous cell carcinoma of the head and neck.
a PS was not available for 1 patient.
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Prospectively planned subgroup analyses showed
that among patients with PS 0 or 1 (n ¼ 690; 86.8% of
the ITT population), those treated with pemetrexed-cis-
platin (n ¼ 347) had a median OS of 8.4 months com-
pared with 6.7 months in patients who received placebo-
cisplatin (n ¼ 343; HR, 0.83; 95% CI, 0.70-0.98; P ¼
.026; interaction P¼ .034; Fig. 2B). In contrast, the PS 2
subgroup (n ¼ 104; 13.1% of the ITT population) had a
median OS of 3.5 months for the pemetrexed-cisplatin
arm and 3.3 months for the placebo-cisplatin arm (P ¼
.243). In addition to the PS 0 or 1 subgroup, there was a
median OS advantage in the subgroup of patients with
oropharynx cancer (n ¼ 192; 24.2% of the ITT popula-
tion) of 9.9 months versus 6.1 months (HR, 0.59; 95%
CI, 0.42-0.82; P ¼ .002; interaction P ¼ .012), peme-
trexed-cisplatin versus placebo-cisplatin, respectively (Fig.
2C). Use of systemic postdiscontinuation therapy was bal-
anced between treatment arms for patients with PS 0 or 1
and oropharynx cancer (Table 2).
Figure 2. Kaplan-Meier plots show overall survival (OS) and progression-free survival (PFS) for total (intention to treat [ITT])
population, and performance status (PS) 0 or 1 and oropharynx subgroups. (A) Kaplan-Meier plot shows OS for ITT population.
(B) Kaplan-Meier plot shows OS for PS 0 or 1 subgroup. (C) Kaplan-Meier plot shows OS for oropharynx subgroup. (D) Kaplan-
Meier plot shows PFS for ITT population. (E) Kaplan-Meier plot shows PFS for PS 0 or 1 subgroup. (F) Kaplan-Meier plot shows
PFS for oropharynx subgroup. CI, confidence interval; Cis, cisplatin; HR, hazard ratio; Pem, pemetrexed.
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A similar analysis was undertaken among the ITT
population for the secondary endpoint PFS. The median
PFS was 3.6 months for the pemetrexed-cisplatin arm and
2.8 months for the placebo-cisplatin arm (HR, 0.88; 95%
CI, 0.76-1.03; P¼ .166; Fig. 2D), with15% censoring
on both arms. After adjusting for baseline prognostic fac-
tors, the treatment effect on PFS was similar to that
observed in the unadjusted analysis (HR, 0.92; 95% CI,
0.79-1.07; P ¼ .290). Prospectively planned subgroup
analyses identified PFS advantage for the pemetrexed-cis-
platin arm compared with the placebo-cisplatin arm in
both the ECOG PS 0 or 1 subgroup (Fig. 2E; HR, 0.84;
95% CI, 0.72-1.00; P ¼ .044; interaction P ¼ .017) and
the oropharynx subgroup (Fig. 2F; HR, 0.73; 95% CI,
0.53-1.00; P¼ .047; interaction P¼ .205).
Figure 3 presents the OS and PFS results within the
PS 0 or 1 subgroup. OS and PFS both favored peme-
trexed-cisplatin over placebo-cisplatin across most of the
subgroups (HRs<1).
Tumor response rate (complete plus partial
response) was not significantly different between arms in
the total population, but was significantly higher for the
pemetrexed-cisplatin arm within the PS 0 or 1 subgroup
(Table 3).
Patient compliance with the FACT-H&N instru-
ment was similar between treatment groups (range, 60%-
89% over 6 cycles). No significant differences in time to
worsening were noted for any FACT-H&N subscale or
total score (Table 4). Likewise, no significant differences
were noted in any change-from-baseline analyses or
FACT-H&N parameters analyzed by PS subgroups (data
not shown).
Safety
Compared with placebo-cisplatin, patients receiving
pemetrexed-cisplatin exhibited significantly greater inci-
dence of drug-related grade 3 or 4 laboratory toxicities
(neutropenia, anemia, and leukopenia), drug-related
grade 3 or 4 nonlaboratory toxicities (febrile neutropenia
and fatigue; Table 5), and need for supportive care (Table
6). Analysis of safety data for various subgroups including
PS (Tables 5 and 6), age, and sex (data not shown) found
subgroups to be consistent with the safety profile observed
in the entire population, with the exception of patients in
the PS 2 subgroup. Patients with PS 2 experienced more
possibly drug-related serious adverse events, more deaths
because of study drug toxicity, and more deaths because
of study disease compared with PS 0 or 1 patients.
Ninety-two patients (23.5%) on the pemetrexed-
cisplatin arm and 96 patients (24.9%) on the placebo-cis-
platin arm died during therapy or within 30 days of treat-
ment discontinuation. The most common cause of death
was disease progression (pemetrexed-cisplatin, 46
[11.7%]; placebo-cisplatin, 75 [19.5%]). Adverse events
accounted for 33 (8.4%) deaths on the pemetrexed-cispla-
tin arm and 19 (4.9%) deaths on the placebo-cisplatin
arm. On study or within 30 days of discontinuation, 1
patient (0.3%) on the placebo-cisplatin arm died because
of possible study drug-related toxicity (cardiorespiratory
arrest), compared with 13 (3.3%) deaths on the peme-
trexed-cisplatin arm (2 deaths each from agranulocytosis,
renal failure, sepsis/septic shock; 1 death each from febrile
neutropenia, bone marrow toxicity, gastrointestinal ne-
crosis, diarrhea, respiratory tract hemorrhage, cardiac fail-
ure, and multiorgan failure). Further review of patient
Table 2. Postdiscontinuation Therapy for ITT Population and Select Subgroups



















Patients receiving 1 poststudy therapy 130 (32.7) 152 (38.3) 122 (35.2) 138 (40.2) 36 (41.9) 41 (38.7)
Patients with no poststudy therapy 268 (67.3) 245 (61.7) 225 (64.8) 205 (59.8) 50 (58.1) 65 (61.3)
Carboplatin 20 (5.0) 19 (4.8) 19 (5.5) 17 (5.0) 8 (9.3) 6 (5.7)
Cetuximab 33 (8.3) 31 (7.8) 30 (8.6) 29 (8.5) 12 (14.0) 9 (8.5)
Cisplatin 36 (9.0) 47 (11.8) 34 (9.8) 43 (12.5) 7 (8.1) 10 (9.4)
Docetaxel 35 (8.8) 33 (8.3) 32 (9.2) 28 (8.2) 8 (9.3) 10 (9.4)
Fluorouracil 28 (7.0) 30 (7.6) 27 (7.8) 28 (8.2) 7 (8.1) 6 (5.7)
Methotrexate 19 (4.8) 31 (7.8) 19 (5.5) 26 (7.6) 5 (5.8) 11 (10.4)
Paclitaxel 22 (5.5) 32 (8.1) 19 (5.5) 31 (9.0) 4 (4.7) 9 (8.5)
Pemetrexed 0 1 (0.3) 0 1 (0.3) 0 0
Abbreviations: Cis, cisplatin; ITT, intention to treat; Pem, pemetrexed; PS, performance status.
No. indicates number of patients with response.
a Systemic therapies used in >5% of a treatment arm are listed, along with pemetrexed.
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Figure 3. Forest plots show data for patients with performance status (PS) 0 or 1. (Top) overall survival; (Bottom) progression-
free survival. The solid vertical line on both figures represents the hazard ratio associated with overall survival (Top) and progres-
sion-free survival (Bottom) for all PS 0 or 1 patients. *Some patients had not been treated with radiotherapy or surgery. CI, confi-
dence interval; Cis, cisplatin; HNC, head and neck cancer; Pem, pemetrexed.
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files revealed 3 of these deaths were unlikely to be related
to study drug toxicity. In addition, 4 of the deaths were in
patients with poor PS (PS 2) at study entry, and 2 deaths
were in patients who did not receive proper dose reduc-
tions and died from agranulocytosis.
DISCUSSION
To our knowledge, this is the largest phase 3, randomized,
double-blind study to date in patients with inoperable
recurrent or metastatic SCCHN. The primary objective
was not achieved, as the ITT analysis of patients on the
pemetrexed-cisplatin arm did not show a significant
improvement in OS over patients on cisplatin monother-
apy. However, in the subgroup of PS 0 or 1 patients,
which comprised 87.2% of the 795 study participants, a
preplanned analysis showed that pemetrexed-cisplatin
treatment led to longer OS and PFS compared with
cisplatin monotherapy, whereas no significant efficacy
differences were noted for PS 2 patients.
Multivariate analyses from palliative chemotherapy
clinical trials have shown that time to progression and OS
are influenced by factors other than the specific chemo-
therapy administered. Poor PS, prior treatment, lack of or
minimal response to treatment, and advanced stage or
metastatic disease are among those factors associated with
worse outcomes in patients with SCCHN treated with
Table 3. Best Overall Tumor Response for ITT Population and PS Subgroups



















CR 2 (0.5) 4 (1.0) 2 (0.6) 3 (0.9) 0 1 (1.9)
PR 46 (11.6) 28 (7.1) 45 (13.0) 26 (7.6) 1 (2.0) 2 (3.8)
CRþPR 48 (12.1) 32 (8.1) 47 (13.5) 29 (8.5) 1 (2.0) 3 (5.7)
P¼.061b P¼.033b P¼.327b
SD 153 (38.4) 135 (34.0) 143 (41.2) 119 (34.7) 10 (19.6) 16 (30.2)
PD 95 (23.9) 128 (32.2) 76 (21.9) 111 (32.4) 19 (37.3) 17 (32.1)
Unknown/not donec 102 (25.6) 102 (25.7) 81 (23.3) 84 (24.5) 21 (41.2) 17 (32.1)
Abbreviations: Cis, cisplatin; CR, complete response; ITT, intention to treat; PD, progressive disease; Pem, pemetrexed; PR, partial response; PS, performance
status; SD, stable disease.
No. indicates number of patients with response.
a PS was not available for 1 patient.
bP value is based on an unadjusted, normal distribution approximation for differences in rates.
cMost patients (95%) without a recorded best overall tumor response were either lost to follow-up or did not have a tumor assessment performed that met
Response Evaluation Criteria in Solid Tumors after the one performed at baseline, or tumor assessment was not done due to early death in the study (assess-
ment incomplete or too soon after baseline visit).
Table 4. HRQL
















Physical well-being 1.77 (256) 2.14 (228) 0.86 [.152] 2.57 {0.26} 2.93 {0.27} .347
Social/family well-being 3.25 (221) 2.76 (201) 0.84 [.122] 0.67 {0.22} 0.82 {0.24} .633
Emotional well-being 3.88 (216) 3.19 (192) 0.86 [.161] 0.03 {0.20} 0.10 {0.21} .652
Functional well-being 2.07 (251) 2.33 (202) 1.11 [.311] 1.61 {0.25} 1.31 {0.26} .405
Additional concerns-H&N 3.25 (174) 2.89 (156) 0.84 [.107] 0.31 {0.32} 1.15 {0.34} .072
Trial Outcome Index-H&N 2.76 (196) 2.40 (168) 0.93 [.494] 4.10 {0.71} 5.55 {0.75} .163
FACT-General 2.40 (238) 2.17 (216) 0.88 [.249] 4.67 {0.64} 5.22 {0.68} .560
Total FACT-H&N 3.3 (177) 2.9 (154) 0.86 [.200] 4.44 {0.99} 6.25 {1.05} .210
Abbreviations: Cis, cisplatin; FACT, Functional Assessment of Cancer Therapy; H&N, Head and Neck; HR, hazard ratio; HRQL, health-related quality of life;
ITT, intention to treat; LS, least-squares; Pem, pemetrexed; SE, standard error; TTW, time to worsening.
a ITT population with at least baseline data.
bQualified ITT population.
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systemic chemotherapy.4 These findings suggest that
patient selection can be at least as important as the type of
therapy administered.
PS is a valid and reliable parameter that may be used
as an inclusion criterion in clinical trials because it not
only defines the physical medical condition of the patient,
but is also a prognostic factor.29,30 The same observation
was made in patients with SCCHN in the Vermorken et
al phase 3 study, in which PS had the greatest prognostic
relevance for OS time.31 In that study, a Karnofsky PS
score 80 was associated with a reduced risk of death by
49% as compared with a Karnofsky score<80 (HR, 0.51;
95% CI, 0.37-0.69; P< .001). Thus, PS 2 patients would
be anticipated to have a worse clinical outcome as a group,
as was confirmed in this study.
The median OS observed in PS 0 or 1 patients
treated with pemetrexed-cisplatin (8.4 months) versus
that for patients treated with placebo-cisplatin (6.7
months) contrasts with the median OS of 3.5 months ver-
sus 3.3 months observed in PS 2 patients receiving the
same treatments. A prespecified interaction test showed a
significant treatment-by-PS (0 or 1 vs 2) interaction, sug-
gesting that pemetrexed-cisplatin effect is significantly
greater in the PS 0 or 1 population compared with that in
PS 2 patients (OS, P ¼ .034; PFS, P ¼ .017). This is a
clinically meaningful difference in this subgroup.
Beyond PS subgroups, other preplanned analyses
looked for evidence of differential treatment benefits in
other subgroups, including primary site of disease.
Patients with oropharyngeal cancer who were treated with
Table 5. Randomized and Treated Patients With CTCAE Grade 3/4 Drug-Related Toxicities (Worst Grade): Total Safety
Population and PS Subgroups





















Neutropenia 45 (11.5) 10 (2.6) <.001 41 (12.0) 10 (3.0) <.001 4 (8.2) 0 .052
Anemia 40 (10.2) 13 (3.4) <.001 35 (10.2) 12 (3.6) .001 5 (10.2) 1 (1.9) .105
Leukopenia 33 (8.4) 5 (1.3) <.001 28 (8.2) 3 (0.9) <.001 5 (10.2) 2 (3.8) .260
Thrombocytopenia 15 (3.8) 6 (1.6) .075 9 (2.6) 5 (1.5) .420 6 (12.2) 1 (1.9) .055
Nonlaboratory
Fatigue 19 (4.8) 7 (1.8) .027 17 (5.0) 4 (1.2) .006 2 (4.1) 3 (5.8) >.999
Febrile neutropenia 12 (3.1) 0 <.001 8 (2.3) 0 .008 4 (8.2) 0 .052
Nausea 10 (2.6) 10 (2.6) >.999 9 (2.6) 6 (1.8) .604 1 (2.0) 4 (7.7) .363
Vomiting 8 (2.0) 10 (2.6) .641 8 (2.3) 8 (2.4) >.999 0 2 (3.8) .495
Diarrhea 5 (1.3) 0 .062 5 (1.5) 0 .062 0 0 —
Anorexia 8 (2.0) 6 (1.6) .789 7 (2.0) 5 (1.5) .773 1 (2.0) 1 (1.9) >.999
Renal failure 5 (1.3) 5 (1.3) >.999 4 (1.2) 5 (1.5) .749 1 (2.0) 0 .485
Abbreviations: Cis, cisplatin; CTCAE, Common Terminology Criteria for Adverse Events, version 3; Pem, pemetrexed; PS, performance status.
Table 6. Hospitalizations and Other Supportive Care: Total Safety Population and PS Subgroups





















G-CSF or GM-CSF 45 (11.5) 15 (3.9) <.001 38 (11.1) 14 (4.2) <.001 7 (14.3) 1 (1.9) .028
Anti-infectivesb 2 (0.5) 1 (0.3) 1.00 2 (0.6) 1 (0.3) 1.00 0 0 —
Analgesics 238 (60.7) 221 (57.4) .381 201 (58.6) 185 (55.6) .438 37 (75.5) 36 (69.2) .512
Transfusions, patients with
1 transfusion
86 (21.9) 58 (15.1) .016 70 (20.4) 52 (15.6) .110 16 (32.7) 6 (11.5) .015
Hospitalizations, patients with 1
hospitalization for drug-related
adverse events, all grades
93 (23.7) 43 (11.2) <.001 79 (23.0) 36 (10.8) <.001 14 (28.6) 7 (13.5) .086
Abbreviations: Cis, cisplatin; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; Pem, pemetrexed;
PS, performance status.
a Erythropoietin use was allowed, but it was not administered to any patient.
b Anti-infectives ¼ antibiotic, antiviral, and antifungal agents.
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pemetrexed-cisplatin showed improvement in both OS
and PFS compared with patients treated with cisplatin
monotherapy. We are not aware of preclinical evidence
that would have predicted this result, nor are there data to
suggest that oropharyngeal tumors express lower levels of
thymidylate synthase, an enzyme in the folate pathway
associated with sensitivity to pemetrexed. However,
human papillomavirus (HPV) has recently been estab-
lished as a risk factor for oropharyngeal cancer, with
emerging data suggesting that HPV-positive tumors are
more sensitive to chemotherapy and radiotherapy than
HPV-negative tumors.32 Whereas the greater responsive-
ness to pemetrexed-cisplatin of the oropharyngeal sub-
group within this study may well be because of the HPV-
positive status of the patients, data on the HPV status of
patients were not collected because this study was initiated
before the full current understanding of this association.
Tumor tissue collection began midtrial to address this
association and others, but no results were obtained
because of difficulties in the RNA analysis. Future studies
will undoubtedly continue to explore the association
between HPV infection and increased sensitivity to chem-
otherapy of oropharyngeal tumors. For now, the respon-
siveness of this tumor type to pemetrexed-cisplatin should
be considered only as hypothesis generating, given the rel-
atively small number of patients in this subgroup.
The toxicity profile of pemetrexed-cisplatin in this
study was consistent with what is already known for this
combination in other tumor types. Pemetrexed-cisplatin
was associated with a higher rate of drug toxicity than pla-
cebo-cisplatin, as expected with combination chemother-
apy. There were more study drug-related deaths, as well as
grade 3 or 4 neutropenia, anemia, leukopenia, febrile neu-
tropenia, and fatigue, and thus a greater need for support-
ive care (granulocyte colony-stimulating factor,
hospitalization, and transfusion). However, as detailed in
Table 5, with the exception of neutropenia (11.5%) and
anemia (10.2%), <10% of patients (total safety popula-
tion) experienced these grade 3 or 4 toxicities. Whereas
the FACT-H&N results did not identify any measurable
difference in HRQL parameters, they also did not identify
any negative HRQL results stemming from the addition
of a second chemotherapeutic agent in the pemetrexed-
cisplatin arm.
Because SCCHN treatment has evolved since this
study was initiated in 2006, cisplatin monotherapy is not
used frequently for treatment, and when administered as
part of a chemotherapy regimen for SCCHN, is often
used at a somewhat higher dose of 100 mg/m2/3 wk, as
in the Vermorken et al study that compared platinum/
fluorouracil/cetuximab with platinum/fluorouracil.31 Al-
though it is difficult to compare these studies because of
the difference in treatment arms, the OS of the chemo-
therapy arm of the Vermorken et al trial (7.4 months) is
similar to that of the pemetrexed-cisplatin arm in our
study (7.3 months). In addition, within the chemotherapy
arm of both studies, the subset of patients with orophar-
ynx cancer had a longer median OS than the median OS
of the total population: Vermorken et al trial, 7.9 versus
7.4 months; our trial, 9.9 versus 7.3 months. Because the
Vermorken et al study showed that the addition of cetuxi-
mab, an antibody targeting the epidermal growth factor
receptor, improved OS to 10.1 months, a phase 2 study
is underway to examine the PFS after treatment with
the combination of cetuximab/pemetrexed/carboplatin
or cetuximab/pemetrexed/cisplatin (ClinicalTrials.gov
identifier: NCT01087970). Another study is investigat-
ing the impact of bevacizumab, an antibody to vascu-
lar endothelial cell growth factor, on pemetrexed-
cetuximab chemoradiotherapy (ClinicalTrials.gov identi-
fier: NCT00703976).
In conclusion, the results of this study in patients
with inoperable recurrent or metastatic SCCHN demon-
strate that pemetrexed-cisplatin combination was not
more efficacious than cisplatin monotherapy for the
whole ITT population. However, it was more efficacious
than platinum monotherapy in patients with PS 0 or 1
and patients with oropharyngeal cancers. In light of the ef-
ficacy of pemetrexed-cisplatin in this trial and the known
mild safety profile of pemetrexed monotherapy, a phase
2 study is investigating the benefits of pemetrexed for
treating higher-risk patients who are less likely to
tolerate triplet therapy (ClinicalTrials.gov identifier:
NCT00293579).
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